Does Wall Street hate health reform?
Opponents of health care reform have suggested that the new law is anti-business. Does the reaction of investors support that view?
Although critics of the Democrats' health care form, which President Obama signed into law on Tuesday, say it features too much intrusive new goverment regulation, higher prices in health care industry stocks on Monday suggest that investors believe that bigger profits lie ahead. Could health reform prove a boon to business? (Watch a Bloomberg report about stocks rising after the health care bill passed)
Don't let the stock blip fool you: It's perfectly understandable that stocks would tick up once the health reform question was settled, says blogger Rossputin in People's Press Collective, because markets hate uncertainty. But the Democrats really want to "end the private health insurance industry, not just tame it," and once it becomes clear that Obamacare moved them closer to that goal health stocks are in for a dive.
"The stock market initially misinterprets ObamaCare"
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sorry, but investors aren't buying GOP fear-mongering: Republicans tried to paint reform advocates as "totalitarian socialist freedom-haters," says Andrew Leonard in Salon, but in the first hours of trading after the health bill passed drug stocks, including "Pfizer, Merck, AstraZeneca, and GlaxoSmithCline were all up, with gusto." The reality is that when you insure more Americans, it's "good for the health of real people, as well as for healthcare industry profits."
"The stock market doesn't fear healthcare reform"
There will be winners and losers on Wall Street: The health care overhaul will cut $132 billion from the Medicare Advantage program, says Matt Phillips in The Wall Street Journal. So while pharmaceutical companies and many hospitals will get a "boost" from the expanded coverage set to begin in 2014, managed care companies, such as Humana, that depend heavily on the Medicare Advantage program for business could be in for a tough time.
"Here are stock market winners in health vote"
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Will California's EV mandate survive Trump, SCOTUS challenge?
Today's Big Question The Golden State's climate goal faces big obstacles
By Joel Mathis, The Week US Published
-
'Underneath the noise, however, there’s an existential crisis'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
2024: the year of distrust in science
In the Spotlight Science and politics do not seem to mix
By Devika Rao, The Week US Published